Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/76533
Title:
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Authors:
Howell, Anthony ( 0000-0002-3879-5991 ) ; Cuzick, Jack; Baum, Michael; Buzdar, Aman; Dowsett, Mitch; Forbes, John F; Hoctin-Boes, G; Houghton, Joan; Locker, Gershon; Tobias, J S
Abstract:
The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.
Affiliation:
Christie Hospital, Manchester, UK. anthony.howell@christie-tr.nwest.nhs.uk
Citation:
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer., 365 (9453):60-2 Lancet
Journal:
Lancet
Issue Date:
Jan-2005
URI:
http://hdl.handle.net/10541/76533
DOI:
10.1016/S0140-6736(04)17666-6
PubMed ID:
15639680
Type:
Article
Language:
en
ISSN:
1474-547X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.contributor.authorCuzick, Jack-
dc.contributor.authorBaum, Michael-
dc.contributor.authorBuzdar, Aman-
dc.contributor.authorDowsett, Mitch-
dc.contributor.authorForbes, John F-
dc.contributor.authorHoctin-Boes, G-
dc.contributor.authorHoughton, Joan-
dc.contributor.authorLocker, Gershon-
dc.contributor.authorTobias, J S-
dc.date.accessioned2009-08-06T12:16:03Z-
dc.date.available2009-08-06T12:16:03Z-
dc.date.issued2005-01-
dc.identifier.citationResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer., 365 (9453):60-2 Lanceten
dc.identifier.issn1474-547X-
dc.identifier.pmid15639680-
dc.identifier.doi10.1016/S0140-6736(04)17666-6-
dc.identifier.urihttp://hdl.handle.net/10541/76533-
dc.description.abstractThe standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women with localised breast cancer. After a median follow-up of 68 months, anastrozole significantly prolonged disease-free survival (575 events with anastrozole vs 651 with tamoxifen, hazard ratio 0.87, 95% CI 0.78-0.97, p=0.01) and time-to-recurrence (402 vs 498, 0.79, 0.70-0.90, p=0.0005), and significantly reduced distant metastases (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 12-62, p=0.01). Almost all patients have completed their scheduled treatment, and fewer withdrawals occurred with anastrozole than with tamoxifen. Anastrozole was also associated with fewer side-effects than tamoxifen, especially gynaecological problems and vascular events, but arthralgia and fractures were increased. Anastrozole should be the preferred initial treatment for postmenopausal women with localised hormone-receptor-positive breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectOestrogen Antagonistsen
dc.subjectCancer Metastasisen
dc.subjectCancer Recurrenceen
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshAromatase Inhibitors-
dc.subject.meshBreast Neoplasms-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshDisease-Free Survival-
dc.subject.meshEstrogen Antagonists-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Metastasis-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshNitriles-
dc.subject.meshPostmenopause-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshSurvival Rate-
dc.subject.meshTamoxifen-
dc.subject.meshTriazoles-
dc.titleResults of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Manchester, UK. anthony.howell@christie-tr.nwest.nhs.uken
dc.identifier.journalLanceten

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.